Introducing human papillomavirus vaccines into the health system in South Africa

Vaccine

Volumn 30, Issue SUPPL.3, 2012, Pages

  Botha, Matthys H ^a   Dochez, Carine ^b  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Cervical cancer; HPV vaccines; South Africa

Indexed keywords

DIPHTHERIA TETANUS VACCINE; PLACEBO; WART VIRUS VACCINE;

CONDYLOMA ACUMINATUM; COST EFFECTIVENESS ANALYSIS; DIZZINESS; DRUG EFFICACY; DRUG USE; FATIGUE; FEVER; HEADACHE; HEALTH CARE SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOGENICITY; INJECTION SITE PAIN; INJECTION SITE SWELLING; MYALGIA; NAUSEA; PRIORITY JOURNAL; REVIEW; SOUTH AFRICA; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY;

FEMALE; HUMANS; IMMUNIZATION PROGRAMS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; SOUTH AFRICA; UTERINE CERVICAL NEOPLASMS;

EID: 84865617147     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.03.032     Document Type: Review

References (75)

1. World Bank. South Africa: Country Brief; 2010. [cited 2011 June]. http://go.worldbank.org/GSBYF92330.
2. Castro-Leal F., Dayton J., Demery L., Mehra K. Public spending on health care in Africa: do the poor benefit?. Bulletin of the World Health Organization 2000, 78(1):66-74.
3. Bradshaw D., Pillay-Van Wyk V., Laubscher R., Nojilana B., Groenewald P., Nannan N., et al. Cause of death statistics for South Africa: challenges and possibilities for improvement 2010, Medical Research Council of South Africa.
4. Stanley M. Prevention strategies against the human papillomavirus: the effectiveness of vaccination. Gynecologic Oncology 2007, 107(2 Suppl):S19-S23.
5. Kay P., Soeters R., Nevin J., Denny L., Dehaeck C.M., Williamson A.L. High prevalence of HPV 16 in South African women with cancer of the cervix and cervical intraepithelial neoplasia. Journal of Medical Virology 2003, 71(2):265-273.
6. Centers for Disease Control and Prevention. What women with a positive HPV test result should know. [cited 2009 March]. http://www.cdc.gov/std/hpv/common-clinicians/InsertPos.pdf.
7. Stanley M. Immunobiology of HPV and HPV vaccines. Gynecologic Oncology 2008, 109(2 Suppl):S15-S21.
8. International Agency for Research on Cancer (IARC) GLOBOCAN 2008, Fast Stats, Southern Africa, http://globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=913 [cited 2011 June].
9. Mqoqi N., Kellett P., Sitas F., Jula M. Incidence of histologically diagnosed cancer in South Africa, 1998-1999 2004, National Cancer Registry of South Africa, National Health Laboratory Service, Johannesburg.
10. Hendricks D., Parker M.I. Oesophageal cancer in Africa. IUBMB Life 2002, 53(4-5):263-268.
11. WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre). Human papillomavirus and related cancers in world; 2010. [cited 2011 November]. http://www.who.int/hpvcentre.
12. Talip Q., Theron G., Steyn W., Hall D. Total perinatally related losses at Tygerberg Hospital - a comparison between 1986: 1993 and 2006. South African Medical Journal 2010, 100(4):250-253.
13. Noehr B., Jensen A., Frederiksen K., Tabor A., Kjaer S.K. Loop electrosurgical excision of the cervix and subsequent risk for spontaneous preterm delivery: a population-based study of singleton deliveries during a 9-year period. American Journal of Obstetrics and Gynecology 2009, 201(1):33e1-33e6.
14. Jakobsson M., Gissler M., Paavonen J., Tapper A.M. Loop electrosurgical excision procedure and the risk for preterm birth. Obstetrics and Gynecology 2009, 114(3):504-510.
15. Kyrgiou M., Koliopoulos G., Martin-Hirsch P., Arbyn M., Prendiville W., Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 2006, 367(9509):489-498.
16. Seedat R.Y., Thukane M., Jansen A.C., Rossouw I., Goedhals D., Burt F.J. HPV types causing juvenile recurrent laryngeal papillomatosis in South Africa. International Journal of Pediatric Otorhinolaryngology 2010, 74(3):255-259.
17. South African Department of Health. Cervical cancer screening programme; 1999. [cited 2011 November]. http://www.doh.gov.za/docs/factsheets/guidelines/cancer.pdf.
18. South African Department of Health. Clinical guidelines for the management of HIV & AIDS in adults and adolescents; 2010. [cited 2011 June]. http://www.fidssa.co.za/Guidelines/2010_Adult_ART_Guidelines.pdf.
19. Bailie R.S., Selvey C.E., Bourne D., Bradshaw D. Trends in cervical cancer mortality in South Africa. International Journal of Epidemiology 1996, 25(3):488-493.
20. Cronje H.S. Screening for cervical cancer in the developing world. Best Practice and Research. Clinical Obstetrics and Gynaecology 2005, 19(4):517-529.
21. Denny L.A., Wright T.C. Human papillomavirus testing and screening. Best Practice and Research. Clinical Obstetrics and Gynaecology 2005, 19(4):501-515.
22. Vijayaraghavan A., Efrusy M., Lindeque G., Dreyer G., Santas C. Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa. Gynecologic Oncology 2009, 112(2):377-383.
23. Clifford G.M., Goncalves M.A., Franceschi S. Human papillomavirus types among women infected with HIV: a meta-analysis. AIDS 2006, 20(18):2337-2344.
24. Moodley J.R., Hoffman M., Carrara H., Allan B.R., Cooper D.D., Rosenberg L., et al. HIV and pre-neoplastic and neoplastic lesions of the cervix in South Africa: a case-control study. BMC Cancer 2006, 6:135.
25. Ellerbrock T.V., Chiasson M.A., Bush T.J., Sun X.W., Sawo D., Brudney K., et al. Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA 2000, 283(8):1031-1037.
26. Averbach S.H., Gravitt P.E., Nowak R.G., Celentano D.D., Dunbar M.S., Morrison C.S., et al. The association between cervical human papillomavirus infection and HIV acquisition among women in Zimbabwe. AIDS 2010, 24(7):1035-1042.
27. Veldhuijzen N.J., Vyankandondera J., van de Wijgert J.H. HIV acquisition is associated with prior high-risk human papillomavirus infection among high-risk women in Rwanda. AIDS 2010, 24(14):2289-2292.
28. van der Loeff M.F., Nyitray A.G., Giuliano A.R. HPV vaccination to prevent HIV infection: time for randomized controlled trials. Sexually Transmitted Diseases 2011, 38(7):640-643.
29. Auvert B., Lissouba P., Cutler E., Zarca K., Puren A., Taljaard D. Association of oncogenic and nononcogenic human papillomavirus with HIV incidence. Journal of Acquired Immune Deficiency Syndromes 2010, 53(1):111-116.
30. World Health Organization Human papillomavirus vaccines. WHO position paper. Weekly Epidemiological Record 2009, 84(15):118-131.
31. World Health Organization. The immunological basis for immunization series. Module 19: human papillomavirus infection. WHO, Department of Immunization, Vaccines and Biologicals; 2011.
32. Paavonen J., Jenkins D., Bosch F.X., Naud P., Salmeron J., Wheeler C.M., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007, 369(9580):2161-2170.
33. Block S.L., Nolan T., Sattler C., Barr E., Giacoletti K.E., Marchant C.D., et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6: 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006, 118(5):2135-2145.
34. Petaja T., Keranen H., Karppa T., Kawa A., Lantela S., Siitari-Mattila M., et al. Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years. Journal of Adolescent Health 2009, 44(1):33-40.
35. Paavonen J., Naud P., Salmeron J., Wheeler C.M., Chow S.N., Apter D., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374(9686):301-314.
36. Paavonen J, on behalf of the HPV PATRICIA Study Group. Efficacy of HPV16/18 ASO4-adjuvanted vaccine against abnormal cytology, colposcopy referrals and cervical procedures. Eurogin 2010;abstract SS 4-1:107.
37. Lehtinen M., Paavonen J., Wheeler C.M., Jaisamrarn U., Garland S.M., Castellsague X., et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncology 2012, 13(1):89-99.
38. De Carvalho N., Teixeira J., Roteli-Martins C.M., Naud P., De Borba P., Zahaf T., et al. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine 2010, 28(38):6247-6255.
39. Dillner J., Kjaer S.K., Wheeler C.M., Sigurdsson K., Iversen O.E., Hernandez-Avila M., et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010, 341:c3493.
40. Steben M. Update on Gardasil (quadrivalent human papillomavirus 6/11/16/18 vaccine) clinical trial efficacy results. Eurogin 2010;abstract SS 3-5:106.
41. Ault K.A. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007, 369(9576):1861-1868.
42. Castellsague X., Munoz N., Pitisuttithum P., Ferris D., Monsonego J., Ault K., et al. End-of-study safety: immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. British Journal of Cancer 2011, 105(1):28-37.
43. Giuliano A.R., Palefsky J.M., Goldstone S., Moreira E.D., Penny M.E., Aranda C., et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. New England Journal of Medicine 2011, 364(5):401-411.
44. Moscicki A.B., Weinberg A., Song L.Y. Safety and immunogenicity of Gardasil in HIV infected Children. Programmes and abstracts of the 25th international papillomavirus conference and clinical workshop 2009, abstract O-16.02.
45. Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix TM) in HIV Infected Females; 2011. [cited 2011 August]. http://clinicaltrials.gov/ct2/show/NCT00586339.
46. Pedersen C., Petaja T., Strauss G., Rumke H.C., Poder A., Richardus J.H., et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. Journal of Adolescent Health 2007, 40(6):564-571.
47. Schwarz T.F., Spaczynski M., Schneider A., Wysocki J., Galaj A., Perona P., et al. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. Vaccine 2009, 27(4):581-587.
48. Harper D.M., Williams K.B. Prophylactic HPV vaccines: current knowledge of impact on gynecologic premalignancies. Discovery Medicine 2010, 10(50):7-17.
49. Olsson S.E., Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Malm C., et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007, 25(26):4931-4939.
50. McKeage K., Romanowski B. AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix(R)): a review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types. Drugs 2011, 71(4):465-488.
51. Einstein M.H., Baron M., Levin M.J., Chatterjee A., Edwards R.P., Zepp F., et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Human Vaccines 2009, 5(10):705-719.
52. Giannini S.L., Hanon E., Moris P., Van Mechelen M., Morel S., Dessy F., et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006, 24(33-34):5937-5949.
53. Kemp T.J., Hildesheim A., Safaeian M., Dauner J.G., Pan Y., Porras C., et al. HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine 2011, 29(11):2011-2014.
54. Wheeler C.M., Castellsague X., Garland S.M., Szarewski A., Paavonen J., Naud P., et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncology 2012, 13(1):100-110.
55. Herrero R. Human papillomavirus (HPV) vaccines: limited cross-protection against additional HPV types. Journal of Infectious Diseases 2009, 199(7):919-922.
56. Brown D.R., Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandez-Avila M., Wheeler C.M., et al. The impact of quadrivalent human papillomavirus (HPV; types 6: 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. Journal of Infectious Diseases 2009, 199(7):926-935.
57. Jit M., Choi Y.H., Edmunds W.J. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 2008, 337:a769.
58. Dochez C., van der Veen F., Meheus A. HPV vaccines and prevention of cervical cancer. Belgian Journal of Medical Oncology 2009, 3(6):275-281.
59. Simoens C., Sabbe M., Van Damme P., Beutels P., Arbyn M. Introduction of human papillomavirus (HPV) vaccination in Belgium, 2007-2008. Eurosurveillance 2009, 14(46).
60. Bogaards J.A., Kretzschmar M., Xiridou M., Meijer C.J., Berkhof J., Wallinga J. Sex-specific immunization for sexually transmitted infections such as human papillomavirus: insights from mathematical models. PLoS Medicine 2011, 8(12):e1001147.
61. Australian National HPV Vaccination Program. Information about the National Human Papillomavirus (HPV) Vaccination Program funded under the Immunise Australia Program; 2011. [cited 2011 July]. http://www.health.gov.au/internet/immunise/publishing.nsf/Content/immunise-hpv.
62. Department of Health. Annual HPV vaccine coverage in England in 2009/2010; 2011. [cited 2011 July]. http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_123826.pdf.
63. Vlaams Agentschap Zorg en Gezondheid; 2011. [cited 2011 August]. http://www.zorg-en-gezondheid.be/HPV/.
64. PATH and Child Health and Development Centre (CHDC) Shaping a strategy to introduce HPV vaccines in Uganda: formative research results from the HPV vaccines: evidence for impact project 2009, PATH, Seattle.
65. Editorial Financing HPV vaccination in developing countries. Lancet 2011;377(9777):1544.
66. Harries J., Moodley J., Barone M.A., Mall S., Sinanovic E. Preparing for HPV vaccination in South Africa: key challenges and opinions. Vaccine 2009, 27(1):38-44.
67. Feinberg M. HPV vaccine suspension in India. Lancet 2010, 376(9753):1644-1645.
68. Schuler C.L., Reiter P.L., Smith J.S., Brewer N.T. Human papillomavirus vaccine and behavioural disinhibition. Sexually Transmitted Infections 2011, 87(4):349-353.
69. Sinanovic E., Moodley J., Barone M.A., Mall S., Cleary S., Harries J. The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South Africa. Vaccine 2009, 27(44):6196-6202.
70. Centers for Disease Control and Prevention FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report (MMWR) 2010, 59(20):626-629.
71. Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Barr E., Alvarez F.B., et al. A controlled trial of a human papillomavirus type 16 vaccine. New England Journal of Medicine 2002, 347(21):1645-1651.
72. International AIDS Vaccine Initiative and PATH. HPV Vaccine Adoption in Developing Countries: Cost and Financing Issues; 2007. [cited 2011 December]. http://www.rho.org/files/IAVI_PATH_HPV_financing.pdf.
73. WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre). Human Papillomavirus and Related Cancers in Russian Federation. Summary Report 2010. [cited 2011 December]. http://www.who.int/hpvcentre.
74. Canfell K., Shi J.F., Lew J.B., Walker R., Zhao F.H., Simonella L., et al. Prevention of cervical cancer in rural China: evaluation of HPV vaccination and primary HPV screening strategies. Vaccine 2011, 29(13):2487-2494.
75. World Health Organization Preparing for the introduction of HPV vaccines: policy and programme guidance for countries 2006, WHO.